Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on May 27, 2020 2:05pm
106 Views
Post# 31079104

RE:Are we there yet ?

RE:Are we there yet ?
Ingiboy wrote: Well Replicel shareholders we are not there yet !

Still waiting for the Japanese Regulatory agencies 3rd and final consultation for Tendon and Skin Cell Therapy products.

Where-o-where are the Dermal Injector testers?

Are there any companies around the world interested in distributing the long awaited Dermal Injector?

Will Yofoto start their Skin and Tendon trials soon?

Has Replicel found any Japanese company to do the Skin and Tendon trials in Japan?

And the "big one" what is the future of RCH-01 ?

Lot's of questions and no answers... oh well, maybe next month.









I know I've said this a lot but I can't see how replicel is going to be able to raise cash. Especially in this environment. Financial markets are in chaos. My hope is that management are actively trying to find a buyer so us shareholders will get something
Bullboard Posts